SEC Tracker
Get the app

Yarrow Bioscience YARW

Yarrow Bioscience reports executive stock option grant

Rebecca Frey (CEO) reported option or other derivative trades in YARW

Form
4
Filed
Importance
Routine
  1. Rebecca Frey, CEO, received 465,857 stock options
  2. Options vest over 4 years starting July 2027
  3. Exercise price is $20 per share
  4. Options expire October 2036

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Yarrow Bioscience files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Rein Therapeutics RNTX public float $32M, Jun 30, 2025
  2. Insight Molecular Diagnostics IMDX public float $32M, Jun 30, 2025
  3. Kezar Life Sciences KZR public float $33M, Jun 30, 2025
  4. Provectus Biopharmaceuticals PVCT public float $31M, Jun 30, 2025
  5. Tempest Therapeutics TPST public float $30M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.